ON DEMAND SYMPOSIUM: Can You Take the Heat? HIPEC In Ovarian Cancer

PRESENTATIONS:
1. IMPLEMENTING HIPEC IN PRACTICE & BUILDING A HIPEC TEAM  
   Speaker: Michael G Kelley, MD
2. PICPAC – THE NEXT FRONTIER  
   Speaker: Thanh Dellinger, MD
3. INTRAOPERATIVE AND POSTOPERATIVE CONSIDERATIONS  
   Speaker: Leslie Randall, MD, MAS
4. APPLICATION AND EVIDENCE FOR HIPEC IN THE TREATMENT OF OVARIAN CANCER  
   Panel Discussion: Oliver Zivanovic, MD

ON DEMAND SYMPOSIUM: Curriculum for Emerging Clinical Trialists

PRESENTATIONS:
1. REGULATORY APPROVAL  
   Speaker: Bradley J Monk, MD, FACS, FACOG
2. GOG PARTNERS  
   Speaker: Thomas Herzog, MD
3. NRG  
   Speaker: Elise C. Kohn, MD

ON DEMAND SYMPOSIUM: Seminal Abstracts: The Best of ASCO, ESMO, IGCS and ESGO

PRESENTATIONS:
1. PHASE III DOUBLE-BLIND KEYNOTE-826 TRIAL PEMBROLIZUMAB FOR PERSISTENT, METASTATIC OR RECURRENT CERVICAL CANCER  
   Speaker: Nicoletta Colombo, MD, PhD
2. EMPOWER-CERVICAL 1/GOG/ENGOT-CX9: RESULTS OF PHASE III TRIAL OF CEMIPLIMAB VS INVESTIGATOR’S CHOICE CHEMOTHERAPY IN RECURRENT/METASTATIC CERVICAL CARCINOMA  
   Speaker: Krishnansu S. Tewari, MD, FACOG, FACS, FRSM
3. DISTILLATION  
   Speaker: Bradley J. Monk, MD, FACS, FACOG
4. **OREO/ENGOT OV-38: A PHASE IIIB TRIAL OF OLAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH EPITHELIAL OVARIAN CANCER**  
   **Speaker:** Eric Pujade-Lauraine, MD, PhD

5. **DISTILLATION**  
   **Speaker:** Stephanie Gaillard, MD, PhD

6. **TISOTUMAB VEDOTIN (TV) + CARBOPLATIN (CARBO) IN FIRST-LINE (1L) OR + PEMBROLIZUMAB (PEMBRO) IN PREVIOUSLY TREATED (2L/3L) RECURRENT OR METASTATIC CERVICAL CANCER (R/MCC): INTERIM RESULTS OF ENGOT-CX8/GOG-3024/INNOVATV 205 STUDY**  
   **Speaker:** Domenica Lorusso, MD, PhD

7. **ASSOCIATION OF HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) WITH CLINICAL OUTCOMES IN A PHASE III STUDY OF OLAPARIB OR CEDIRANIB AND OLAPARIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY IN RECURRENT PLATINUM-SENSITIVE OVARIAN CANCER (PSOC): BIOMARK**  
   **Speaker:** Joyce F. Liu, MD MPH

8. **MIRVETUXIMAP SORVATANSINE, A FOLATE RECEPTOR ALPHA-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH PLATINUM-AGNOSTIC OVARIAN CANCER: FINAL ANALYSIS**  
   **Speaker:** David M. O’Malley, MD

9. **MAINTENANCE VIGIL IMMUNOTHERAPY IN NEWLY DIAGNOSED ADVANCED OVARIAN CANCER: EFFICACY ASSESSMENT OF HOMOLOGOUS RECOMBINATION PROFICIENT (HRP) PATIENTS IN THE PASE IIB VITAL TRIAL**  
   **Speaker:** Rodney P. Rocconi, MD

**ON DEMAND SYMPOSIUM:** SGO Business Meeting

**PRESENTATIONS:**

1. **BUSINESS MEETING REPORT**  
   **Speaker:** Seiko D. Yamada, MD

2. **NOMINATING COMMITTEE REPORT**  
   **Speaker:** David E. Cohn, MD, MBA

3. **GOG REPORT**  
   **Speaker:** Larry J. Copeland, MD
SPECIAL INTEREST SESSION: Master Class: Breaking Barriers: Developing World Class Clinical Research Programs & Closing the Diversity Gap

Friday, March 18, 8:00 AM – 12:00 PM

PRESENTATIONS:

1. **CREATING A “CULTURE OF RESEARCH”: PROGRAMMATIC BARRIERS**  
   **Speaker:** Stephanie Gaillard, MD, PhD

2. **CREATING A “CULTURE OF RESEARCH”: COST CONSIDERATIONS**  
   **Speaker:** Robert L. Coleman, MD

3. **CREATING A “CULTURE OF RESEARCH”: INTEGRATION INTO CLINICAL PRACTICE: LESSONS FROM COACH K**  
   **Speaker:** Angeles Alvarez Secord, MD

4. **CREATING A “CULTURE OF RESEARCH”: PRIVATE PRACTICE CONSIDERATIONS**  
   **Speaker:** Colleen C. McCormick, MD, MPH

5. **PROJECT ECHO, FOSTER TRIAL**  
   **Speaker:** Ursa A. Brown-Glaberman, MD

6. **ENDOMETRIAL SOMATIC PROFILE DIFFERENCES BY RACE: A FIRST STEP TO NARROW THE DISPARITY GAP**  
   **Speaker:** Jennifer C. Gordon, MD

7. **IMPACT OF DISPARITIES IN GENOMIC RESEARCH ON CLINICAL RESEARCH**  
   **Speaker:** Melissa B. Davis, PhD

8. **LEVELING THE PLAYING FIELD: IDENTIFYING BARRIERS AND PATTERNS OF ENDOMETRIAL CANCER CLINICAL TRIAL ENROLLMENT FOR UNDERREPRESENTED GROUPS**  
   **Speaker:** Sarah S. Lee, MD, MBA

9. **CRITICAL DECISIONS: A MIXED-METHODS STUDY INVESTIGATING DECISION-MAKING AND DISPARITIES AMONG DIVERSE GYNECOLOGIC CANCER PATIENTS CONSIDERING THERAPEUTIC CLINICAL TRIAL ENROLLMENT**  
   **Speaker:** Stephanie Rieder, MD, PhD

10. **A COLLABORATIVE APPROACH TO ENGAGING AMERICAN INDIANS OF SOUTHWESTERN TRIBAL NATIONS IN CLINICAL RESEARCH INITIATIVES**  
    **Speaker:** Andrew L. Sussman, PhD, MCRP

11. **ENHANCING MINORITY PARTICIPATION IN CLINICAL TRIALS: STRATEGIES FROM THE EMPACT CONSORTIUM AND NRG ONCOLOGY**  
    **Speaker:** Jennifer Wenzel, PhD, RN, CCM, FAAN
Friday, March 18, 3:10 PM – 4:45 PM

PRESENTATIONS:

1. **LONG TERM SURVIVAL OF GOG 252 “RANDOMIZED TRIAL OF INTRAVENOUS VERSUS INTRAPERITONEAL CHEMOTHERAPY PLUS BEVACIZUMAB IN ADVANCED OVARIAN CARCINOMA: AN NRG ONCOLOGY/GOG STUDY”**
   **Speaker:** Joan L. Walker, MD

2. **WHAT’S NEXT AFTER BEVACIZUMAB RESISTANCE? TARGETING METABOLIC VULNERABILITIES IN OVARIAN CANCER**
   **Speaker:** Deanna Glassman, MD

3. **PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, KEYNOTE-826 TRIAL OF PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER**
   **Speaker:** Bradley J. Monk, MD, FACS, FACOG

4. **SAFETY AND IMMUNOGENICITY OF ANTI PD-L1 (ATEZOLIZUMAB) GIVEN AS AN IMMUNE PRIMER OR CONCURRENTLY WITH EXTENDED FIELD CHEMORADIOThERAPY FOR NODE POSITIVE LOCALLY ADVANCED CERVICAL CANCER: AN NRG ONCOLOGY TRIAL**
   **Speaker:** Jyoti Mayadev, MD

5. **PEMBROLIZUMAB FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: A COST-EFFECTIVENESS ANALYSIS**
   **Speaker:** David A. Barrington, MD

6. **DISTILLATION**
   **Speaker:** Leslie Randall, MD, MAS

7. **FINAL OVERALL SURVIVAL RESULTS FROM SOLO3: PHASE III TRIAL ASSESSESSING OLAPARIB MONOTHERAPY VERSUS NON-PLATINUM CHEMOTHERAPY IN HEAVILY PRETREATED PATIENTS WITH GERMLINE BRCA1 AND/OR BRCA2-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER**
   **Speaker:** Richard T Penson, MD

8. **INVESTIGATION OF PARP INHIBITOR RESISTANCE THROUGH THE ANALYSIS OF SERIALLY COLLECTED CIRCULATING TUMOR DNA (ctDNA) in OVARIAN CANCER PATIENTS**
   **Speaker:** Yoo-Na Kim, MD

   **Speaker:** Kathleen N. Moore, MD
10. KNOWLEDGE MEASURE FOR OVARIAN CANCER RESEARCH (KNOMOR): DEVELOPMENT AND PSYCHOMETRIC TESTING RESULTS OF A PATIENT-CENTERED KNOWLEDGE MEASURE  
Speaker: Larissa A. Meyer, MD, MPH

11. DISTILLATION  
Speaker: Michael A. Bookman, MD

12. DISTILLATION  
Speaker: Elise C. Kohn, MD

FOCUSED PLENARY I: International Studies with Global Impact

Friday, March 18, 5:00 PM – 6:00 PM

PRESENTATIONS:

1. CLINICAL AND MOLECULAR CHARACTERISTICS OF AMBITION PATIENTS WHO RECEIVED OLAPARIB PLUS CEDIRANIB OR OLAPARIB PLUS DURVALUMAB FOR HOMOLOGOUS RECOMBINATION REPAIR MUTATED, PLATINUM-RESISTANT OVARIAN CANCER (KGOG 3045)  
Speaker: Se Ik Kim, MD, PhD

2. ANLOTINIB IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OR -REFRACTORY OVARIAN CARCINOMA: A PROSPECTIVE, SINGLE-CENTER, SINGLE-ARM, PHASE II CLINICAL TRIAL  
Speaker: Boer Shan, MD

3. DISTILLATION  
Speaker: Isabelle Ray-Coquard, MD, PhD

4. Distillation  
Speaker: Jerome L. Belinson, MD

5. LIO-1: INITIAL PHASE 2 EXPERIENCE OF LUCITANIB + NIVOLUMAB IN PATIENTS WITH METASTATIC OR RECURRENT CERVICAL CANCER (NCT04042116; ENGOT-GYN3/AGO/LIO)  
Speaker: Ana Oaknin, MD, PhD

6. GENOMIC PROFILING AND PD-L1 EXPRESSION OF ADVANCED CERVICAL CANCER TO PREDICT RESPONSE TO PROGRAMMED DEATH-1 INHIBITOR COMBINATION THERAPY: A SECONDARY ANALYSIS OF THE CIBI308ALTER-C201 TRIAL  
Speaker: Qin Xu, PhD

7. PENETRATING COMPLICATIONS OF BEVACIZUMAB-CONTAINING CHEMOTHERAPY IN PREVIOUSLY-IRRADIATED RECURRENT CERVICAL CANCER: A KOREAN MULTICENTER RETROSPECTIVE STUDY OF THE GYNECOLOGIC ONCOLOGY RESEARCH INVESTIGATORS  
Speaker: Nam Kyeong Kim, MD
8. DISTILLATION  
Speaker: Charles A. Leath, III, MD, MSPH

9. PILOT CERVICAL CANCER NAVIGATION PROGRAM OUTCOMES FROM A TERTIARY TANZANIAN ACADEMIC INSTITUTE  
Speaker: Anjali Hari, MD

13. INTEGRATING CERVICAL CANCER SCREENING AND PREVENTION TREATMENT WITH VOLUNTARY FAMILY PLANNING IN MOZAMBIQUE  
Speaker: Mila P. Salcedo, MD, PhD

FOCUSED PLENARY III: Inequities During the Pandemic and Beyond

Saturday, March 19, 9:00 AM – 10:30 AM

PRESENTATIONS:
1. IMPACT OF COVID-19 ON GYNECOLOGIC ONCOLOGY PATIENTS: AN SGO COVID-19 AND GYNECOLOGIC CANCER REGISTRY STUDY  
Speaker: Gretchen E. Glaser, MD

2. WE CAN’T JUST WAIT THIS OUT: BURNOUT AND FULFILLMENT AMONG SGO MEMBERS OVER THE FIRST TWO WAVES OF THE COVID-19 PANDEMIC  
Speaker: Caitlynn Carr, MD

3. PERSISTANT INEQUITIES IN ACCESS TO AND CONTINUITY OF GYNECOLOGIC ONCOLOGY CARE DURING THE COVID-19 PANDEMIC  
Speaker: Shaina F. Bruce, MD

4. JUGGLING ACT: COVID-19’S IMPACT ON THE QUALITY OF LIFE OF GYNECOLOGIC ONCOLOGISTS  
Speaker: Lia Bos, MD

5. GYNECOLOGIC ONCOLOGY PATIENTS LIVING IN RURAL AREAS LESS LIKELY TO UTILIZE TELEMEDICINE SERVICES DURING THE COVID-19 PANDEMIC  
Speaker: Anna Kuan-Celarier, MD

6. PANDEMIC SOLUTIONS: THINGS HERE TO STAY  
Speaker: Warner K. Huh, MD

7. REFUSAL OF GYNECOLOGIC CANCER SURGERY IS A SURGICAL AND ONCOLOGIC DISPARITY, NOT AN ISSUE OF NONCOMPLIANCE  
Speaker: David Samuel, MD

8. DOES RACE IMPACT UTERINE CANCER SURGICAL TREATMENT: AN SGO CLINICAL OUTCOMES REGISTRY ANALYSIS  
Speaker: Mona Saleh, MD
9. SOCIO-ECOLOGICAL MODEL OF BARRIERS TO CASCADE TESTING FOR HEREDITARY CANCER SYNDROMES: SYSTEMATIC REVIEW OF THE LITERATURE  
   **Speaker:** Xuan Li, MD

10. GEOSPATIAL APPROACHES FOR SURVEILLANCE OF DISPARITIES IN CLINICAL TRIAL ENROLLMENT  
    **Speaker:** Jennifer C. Gordon, MD

11. DISPARITIES IN THE QUALITY OF DEFINITIVE RADIATION THERAPY FOR PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER  
    **Speaker:** Dimitrios Nasioudis, MD

12. WHEN BEING INSURED IS NOT ENOUGH: THE EFFECT OF INSURANCE TYPE ON SURVIVAL IN CERVICAL CANCER  
    **Speaker:** Calen W. Kucera, MD, MPH, FACOG

13. RACE MATTERS: DISPARITIES IN THE USE OF MAINTENANCE THERAPY IN OVARIAN CANCER (OC)  
    **Speaker:** Evan A. Schrader, MD

14. DISTILLATION  
    **Speaker:** Nita K. Lee, MD, MPH

**SCIENTIFIC PLENARY III: Novel Therapeutics: The Expanding Toolbox**

**Saturday, March 19, 11:00 AM – 12:15 PM**

**PRESENTATIONS:**

1. **PHASE 2, TWO-STAGE STUDY OF LETROZOLE AND ABEMACICLIB IN ESTROGEN RECEPTOR (ER) POSITIVE RECURRENT OR PERSISTENT ENDOMETRIAL CANCER**  
   **Speaker:** Panagiotis A. Konstantinopoulos, MD, PhD

2. **EGFL6 IS AN IMPORTANT GROWTH FACTOR INVOLVED IN ENDOMETRIAL CANCER TOMORIGENESIS**  
   **Speaker:** Alison A. Garrett, MD

3. **DISTILLATION**  
   **Speaker:** Shannon N. Westin, MD, MPD

4. **A NOVEL COMBO OF NIRAPARIB AND ANLOTINIB IN PLATINUM-RESISTANT OVARIAN CANCER, THE FINAL EFFICACY AND SAFETY REPORT OF ANNIE STUDY, A PHASE II, MULTI-CENTER TRIAL**  
   **Speaker:** Ji Hong Liu
5. **Efficacy and Safety of Serplulimab (an Anti-PD-1 Antibody) Combined with Albumin-Bound Paclitaxel in Patients with Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy**  
   **Speaker:** Jusheng An

   **Speaker:** Xiaohua Wu

7. **Distillation**  
   **Speaker:** Nicoletta Colombo, MD, PhD

8. **Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (Upri;XMT-1536) a Napi2b-Directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer**  
   **Speaker:** Debra L. Richardson, MD

9. **Clinical Outcomes of Ovarian Cancer Patients Treated with the Novel Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab: Recent Data from Artistry-1**  
   **Speaker:** Ira S. Winer, MD, PhD

10. **Distillation**  
    **Speaker:** Katherine C. Fuh, MD, PhD

**Scientific Plenary IV: Late-Breaking Abstracts**

**Saturday, March 19, 4:15 AM – 5:45PM**

**Presentations:**

12. **A Randomized Phase 3 Trial of Intraperitoneal Versus Intravenous Carboplatin with Dose-Dense Weekly Paclitaxel in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (A Gotic-001/Jgog-3019/Gcig, IppoC Trial)**  
    **Speaker:** Keiichi Fujiwara, MD, PhD

13. **Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the Soraya Study**  
    **Speaker:** Ursula A. Matulonis

14. **Distillation**  
    **Speaker:** Deborah K. Armstrong, MD
15. EFFICACY AND SAFETY OF NIRAPARIB AS MAINTENANCE TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER USING AN INDIVIDUALIZED STARTING DOSE (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial
   Speaker: Ning Li, MD

16. PREDICTIVE VALUE OF THE LEUVEN HRD TEST COMPARED WITH MYRIAD MYCHOICE PLUS ON 468 OVARIAN CANCER SAMPLES FROM THE PAOLA-1/ENGOT-OV25 TRIAL
   Speaker: Liselore Loverix, MD

17. THE GENOMIC LANDSCAPE OF LOW-GRADE SEROUS OVARIAN/PERITONEAL CARCINOMA (LGSOC) AND ITS IMPACT ON CLINICAL OUTCOMES
   Speaker: David M. Gershenson, MD

18. GENOMIC ALTERATIONS, MOLECULARLY TARGETED THERAPY AND RACE: REAL WORLD DATA FROM THE ENDOMETRIAL CANCER MOLECULARLY TARGETED THERAPY CONSORTIUM
   Speaker: Angeles Alvarez Secord, MD

19. DISTILLATION
   Speaker: Barbara M. Noquist, MD

20. OPEN VS. MINIMALLY INVASIVE RADICAL HYSTERECTOMY IN EARLY CERVICAL CANCER: LACC TRIAL FINAL ANALYSIS
    Speaker: Pedro T. Ramirez, MD

21. DISTILLATION
    Speaker: Kristin L. Bixel, MD

22. PROSPECTIVE DOUBLE-BLIND, RANDOMIZED PHASE III ENGOT-EN5/GOG-3055/SIENDO STUDY OF ORAL SELINEXOR/PLACEBO AS AMINENCE THERAPY AFTER FIRST-LINE CHEMOTHERAPY FOR ADVANCED OR RECURRENT ENDOMETRIAL CANCER
    Speaker: Ignace B. Vergote, MD, PhD

SPECIAL INTEREST SESSION: Curriculum for Emerging Clinical Trialists

Sunday, March 20, 7:00 AM – 10:00 AM

PRESENTATIONS:
1. STATISTICS FOR PHASE I TRIALS
   Speaker: Jeanelle Sheeder, PhD

2. USING BIOMARKERS IN CERVICAL CANCER TRIALS
   Speaker: Charles A. Leath, III, MD, MSPH

3. USING BIOMARKERS IN UTERINE CANCER TRIALS
   Speaker: Angeles Alvarez Secord, MD
4. **DESIGNING OVARY TRIALS IN THE ERA OF BIOMARKERS**  
   **Speaker:** Kathleen N. Moore, MD

**SCIENTIFIC PLENARY VI:** Tumor Board – SGO Feud: Midwest Versus The Rest!

Sunday, March 20, 5:30 PM – 7:00 PM

**PRESENTATIONS:**
1. **Tumor Board – SGO Feud: Midwest Versus The Rest!**  
   **Speaker:** Kenneth H. Kim, MD, MHPE